Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback